L-NMMA (citrate)
(Synonyms: L-NG-monomethyl Arginine citrate) 目录号 : GC11163A non-selective NOS inhibitor
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-NMMA (citrate) is a relatively non-selective inhibitor of all NOS isoforms [1].
Nitric oxide synthases (NOSs) belong to a family of enzymes involved in catalyzing the production of nitric oxide (NO) from L-arginine. As an important cellular signaling molecule, NO has been implicated in modulating vascular tone, insulin secretion, airway tone, and peristalsis, angiogenesis and neural development. Until now, three isozymes of NOS have been identified: eNOS (endothelial NOS), nNOS (neuronal NOS), and iNOS (inducible NOS). The eNOS plays a critical role in embryonic heart development and morphogenesis of coronary arteries and cardiac valves. The nNOS functions as a retrograde neurotransmitter important in long term potentiation and has been involved in the development of nervous system. The iNOS produces large amounts of NO as a defense mechanism and is an important factor in the response of the body to attack by parasites, bacterial infection, and tumor growth [2].
L-NMMA inhibited the activity of NOS with the Ki values of approximately 0.18, 0.4, and 6 μM for nNOS (rat), eNOS (human), and iNOS (mouse), respectively [1]. In perfused dog mesenteric artery segments, treatment with L-NMMA increased the vasoconstriction induced by adrenergic nerve stimulation. In dog cerebral artery strips, L-NMMA suppressed the relaxant response to transmural nerve stimulation [3]. In patients with cardiogenic shock, L-NMMA administration is safe and has favorable clinical and hemodynamic effects [4].
References:
[1] Frey C, Narayanan K, McMillan K, et al. L-thiocitrulline. A stereospecific, heme-binding inhibitor of nitric-oxide synthases[J]. Journal of Biological Chemistry, 1994, 269(42): 26083-26091.
[2] Stuehr D J, Griffith O W. Mammalian nitric oxide synthases[J]. Advances in Enzymology and Related Areas of Molecular Biology, Volume 65, 2006: 287-346.
[3] TODA N, OKAMURA T. Modification by L-NG-monomethyl arginine (L-NMMA) of the response to nerve stimulation in isolated dog mesenteric and cerebral arteries[J]. The Japanese Journal of Pharmacology, 1990, 52(1): 170-173.
[4] Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock[J]. Circulation, 2000, 101(12): 1358-1361.
| Cas No. | SDF | ||
| 别名 | L-NG-monomethyl Arginine citrate | ||
| 化学名 | N5-[imino(methylamino)methyl]-L-ornithine, citrate | ||
| Canonical SMILES | CN([H])/C(N([H])CCC[C@@H](C(O)=O)N)=N/[H].OC(CC(O)=O)(C(O)=O)CC(O)=O | ||
| 分子式 | 3[C7H16N4O2] · C6H8O7 | 分子量 | 756.8 |
| 溶解度 | ≤6mg/ml in PBS | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3214 mL | 6.6068 mL | 13.2135 mL |
| 5 mM | 0.2643 mL | 1.3214 mL | 2.6427 mL |
| 10 mM | 0.1321 mL | 0.6607 mL | 1.3214 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。